The Direct Answer
Long COVID impairs neuroplasticity through at least four mechanisms: neuroinflammation reduces BDNF expression, synaptic damage disrupts neural circuit integrity, mitochondrial dysfunction impairs the energy-intensive process of synaptic remodelling, and persistent stress hormones suppress hippocampal neurogenesis. Psilocybin is one of the most potent neuroplasticity promoters identified in preclinical and early human research — it increases BDNF, promotes dendritic spine growth, and enhances brain network flexibility. The mechanistic overlap is substantial.
What Neuroplasticity Actually Means
Neuroplasticity is the brain's ability to reorganise itself by forming new neural connections. It is not a single process but a collection of mechanisms including:
- Synaptic plasticity: Strengthening or weakening of existing synaptic connections (long-term potentiation and depression)
- Structural plasticity: Growth of new dendritic spines and axonal branches
- Neurogenesis: Formation of new neurons (primarily in the hippocampus)
- Network flexibility: The brain's ability to shift between different functional states and form new patterns of connectivity
All four of these are impaired in long COVID.
How Long COVID Impairs Neuroplasticity
| Mechanism | Effect on Neuroplasticity | Evidence |
|---|---|---|
| Neuroinflammation (elevated IL-6, TNF-α) | Reduces BDNF expression; impairs LTP; promotes synaptic pruning | Multiple studies; CSF cytokine elevation documented |
| Microglial activation | Excessive synaptic pruning; disruption of neural circuit integrity | King's College London, 2023 |
| Mitochondrial dysfunction | Insufficient ATP for energy-intensive synaptic remodelling | Multiple long COVID studies |
| HPA axis dysregulation (elevated cortisol) | Suppresses hippocampal neurogenesis; reduces dendritic branching | Well-established in stress neuroscience |
| Serotonin depletion | Serotonin is required for synaptic plasticity and BDNF expression | Cell, 2023 (Bhatt et al.) |
How Psilocybin Promotes Neuroplasticity
Psilocybin's neuroplasticity effects have been documented at multiple levels:
- BDNF upregulation: A 2021 study found that psilocybin increased BDNF expression in the prefrontal cortex by 40% in rodent models. Human studies show elevated BDNF in plasma following psilocybin administration.
- Dendritic spine growth: A landmark 2021 study in Neuron (Ly et al.) found that psilocybin promoted rapid and sustained growth of dendritic spines in the prefrontal cortex — the same region most affected by long COVID cognitive impairment. Spine density increased by 10% and remained elevated at 30 days post-treatment.
- Brain network flexibility: A 2022 Nature Medicine study found that psilocybin therapy produced sustained increases in brain network flexibility — the ability to shift between functional states — that correlated directly with improvements in depression and cognitive function.
- Default mode network modulation: Psilocybin disrupts the rigid, hyperactive DMN patterns associated with both depression and cognitive rigidity, creating a window of increased neural flexibility.
- Anti-inflammatory effects: By reducing microglial activation and pro-inflammatory cytokine expression, psilocybin may remove one of the primary obstacles to neuroplasticity in long COVID.
The Timing Question
One important consideration for long COVID patients is the timing of neuroplasticity interventions. The brain's capacity for repair is not uniform over time — it appears to be highest in the first 12–18 months post-injury, when inflammatory processes are still active and the brain is most responsive to neuroplasticity signals. This suggests that earlier intervention may produce better outcomes, though this has not been tested specifically in long COVID.
According to Shrooomz's microdosing protocol, the neuroplasticity window is one reason why starting a consistent microdosing regimen early in the long COVID recovery process may be more beneficial than waiting until symptoms have been present for years.
What This Means Practically
The mechanistic case for psilocybin in long COVID cognitive symptoms is strong. The clinical evidence is preliminary but encouraging. The practical implication for long COVID patients is:
- The neuroplasticity mechanisms that psilocybin activates are precisely the mechanisms that long COVID impairs
- The anti-inflammatory effects may address the upstream cause of neuroplasticity impairment
- The window for maximum benefit may be earlier rather than later in the recovery process
Related reading: Psilocybin for long COVID brain fog | Psilocybin neuroplasticity overview | Long COVID depression